IDRA Idera Pharmaceuticals Inc.

2.48
-0.01  -0%
Previous Close 2.49
Open 2.48
Price To Book 1.25
Market Cap 69,493,955
Shares 28,021,756
Volume 9,215
Short Ratio
Av. Daily Volume 388,788

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 final data due 4Q 2019.
Tilsotolimod + ipilimumab - ILLUMINATE 204
Cancer - melanoma
Development suspended - September 2016.
IMO-8400
Waldenström’s Macroglobulinemia
Development suspended - September 2016.
IMO-8400
Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 data released June 12, 2018 - primary endpoint not met.
IMO-8400
Dermatomyositis
Phase 1b data at AACR April 2019 noted 45% disease control rate.
Tilsotolimod - ILLUMINATE 101
Solid tumors
Phase 3 completion of enrolment due 4Q 2019.
Tilsotolimod (IMO-2125) + ipilimumab - ILLUMINATE 301
Melanoma
Phase 2 trial to be initiated 2H 2019.
Tilsotolimod + nivolumab and ipilimumab - ILLUMINATE 206
Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Latest News

  1. Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
  2. Idera Pharmaceuticals, Inc. (IDRA) Shares March Higher, Can It Continue?
  3. Idera Pharmaceuticals (IDRA) Reports Q1 Loss, Lags Revenue Estimates
  4. Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
  5. Will Idera Pharmaceuticals (IDRA) Report Negative Q1 Earnings? What You Should Know
  6. Need To Know: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Insiders Have Been Buying Shares
  7. Idera Pharmaceuticals Provides Corporate Update
  8. Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting
  9. Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year
  10. If You Had Bought Idera Pharmaceuticals Stock Five Years Ago, You’d Be Sitting On A 94% Loss, Today
  11. Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
  12. Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
  13. Idera acquires Travis CI
  14. How Much is Idera Pharmaceuticals, Inc.’s (NASDAQ:IDRA) CEO Getting Paid?
  15. Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
  16. Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors
  17. Today's Research Reports on Trending Tickers: Johnson & Johnson and Idera Pharmaceuticals
  18. Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
  19. Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018
  20. United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries — Future Expectations, Projections Moving into 2018